202 related articles for article (PubMed ID: 35878022)
1. IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer.
Ong LT; Lee WC; Ma S; Oguz G; Niu Z; Bao Y; Yusuf M; Lee PL; Goh JY; Wang P; Yong KSM; Chen Q; Wang W; Ramasamy A; Hoon DSB; Ditzel HJ; Tan EY; Lee SC; Yu Q
Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2201376119. PubMed ID: 35878022
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion.
Chaganty BKR; Qiu S; Gest A; Lu Y; Ivan C; Calin GA; Weiner LM; Fan Z
Cancer Lett; 2018 Aug; 430():47-56. PubMed ID: 29746929
[TBL] [Abstract][Full Text] [Related]
3. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
4. The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer.
Hu X; Liu Y; Zhang X; Kong D; Kong J; Zhao D; Guo Y; Sun L; Chu L; Liu S; Hou X; Ren F; Zhao Y; Lu C; Zhai D; Yuan X
Neoplasia; 2020 Nov; 22(11):539-553. PubMed ID: 32966956
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
[TBL] [Abstract][Full Text] [Related]
6. The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low-Expressing Cancer
Dreyer TF; Kuhn S; Stange C; Heithorst N; Schilling D; Jelsma J; Sievert W; Seitz S; Stangl S; Hapfelmeier A; Noske A; Wege AK; Weichert W; Ruland J; Schmitt M; Dorn J; Kiechle M; Reuning U; Magdolen V; Multhoff G; Bronger H
Cancer Immunol Res; 2021 Jul; 9(7):779-789. PubMed ID: 33906866
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Potential Target Genes of Borneol in Increasing Trastuzumab Sensitivity in HER2+ Trastuzumab-Resistant Breast Cancer: Bioinformatics and In Vitro Studies.
Lestari IA; Putra IMR; Fatimah N; Ujiantari NSO; Putri DDP; Hermawan A
Asian Pac J Cancer Prev; 2024 May; 25(5):1623-1634. PubMed ID: 38809634
[TBL] [Abstract][Full Text] [Related]
8. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
9. NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer.
Jiang L; Ren L; Chen H; Pan J; Zhang Z; Kuang X; Chen X; Bao W; Lin C; Zhou Z; Huang D; Yang J; Huang H; Wang L; Hou N; Song L
Cell Death Dis; 2020 Jul; 11(7):547. PubMed ID: 32683421
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen overcomes the trastuzumab-resistance of SK-BR-3 tumorspheres by targeting crosstalk between cytoplasmic estrogen receptor α and the EGFR/HER2 signaling pathway.
Kwon YS; Nam KS; Kim S
Biochem Pharmacol; 2021 Aug; 190():114635. PubMed ID: 34058187
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
[TBL] [Abstract][Full Text] [Related]
12. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
Gardaneh M; Shojaei S; Kaviani A; Behnam B
Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
[TBL] [Abstract][Full Text] [Related]
13. Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer.
Zazo S; González-Alonso P; Martín-Aparicio E; Chamizo C; Luque M; Sanz-Álvarez M; Mínguez P; Gómez-López G; Cristóbal I; Caramés C; García-Foncillas J; Eroles P; Lluch A; Arpí O; Rovira A; Albanell J; Madoz-Gúrpide J; Rojo F
Mol Cancer Ther; 2020 Aug; 19(8):1696-1707. PubMed ID: 32404410
[TBL] [Abstract][Full Text] [Related]
14. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
15. Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.
Berns K; Sonnenblick A; Gennissen A; Brohée S; Hijmans EM; Evers B; Fumagalli D; Desmedt C; Loibl S; Denkert C; Neven P; Guo W; Zhang F; Knijnenburg TA; Bosse T; van der Heijden MS; Hindriksen S; Nijkamp W; Wessels LF; Joensuu H; Mills GB; Beijersbergen RL; Sotiriou C; Bernards R
Clin Cancer Res; 2016 Nov; 22(21):5238-5248. PubMed ID: 27172896
[TBL] [Abstract][Full Text] [Related]
16. HER2 Signaling in Breast Cancer.
Shin I
Adv Exp Med Biol; 2021; 1187():53-79. PubMed ID: 33983573
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
18. HER2-positive breast cancer cells expressing elevated FAM83A are sensitive to FAM83A loss.
Bartel CA; Jackson MW
PLoS One; 2017; 12(5):e0176778. PubMed ID: 28463969
[TBL] [Abstract][Full Text] [Related]
19. circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer.
Ling Y; Liang G; Lin Q; Fang X; Luo Q; Cen Y; Mehrpour M; Hamai A; Liu Z; Shi Y; Li J; Lin W; Jia S; Yang W; Liu Q; Song E; Li J; Gong C
Mol Cancer; 2022 Jan; 21(1):8. PubMed ID: 34980129
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
